– USA, NY – Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Catherine D. Strader, Ph.D., has joined its board of directors, effective February 17. Dr. Strader is currently a founding partner at Synergy Partners R&D Solutions.
“I am delighted to welcome Dr. Strader to Acorda’s board of directors,” said Ron Cohen, M.D., Acorda’s President and CEO. “Catherine brings decades of experience as both a drug developer and biopharmaceutical business executive with an outstanding track record of achievement. I expect her to add significant value to the Board and the Company as we continue to develop our pipeline and grow our business.”
“I am excited to be joining Acorda’s board of directors,” said Dr. Strader. “The Company has a promising pipeline of innovative neurological therapies. I’m looking forward to working with Ron, the Board and the management team to help advance these programs.”
Dr. Strader will be filling a newly-added Board seat and will be up for re-election in 2018.
Prior to founding Synergy Partners R&D Solutions, Dr. Strader held executive leadership positions at both Merck, where she was Vice President and Site Head, and Schering-Plough, where she was Executive Vice President of Discovery Research and Chief Scientific Officer. She has guided more than 50 compounds through drug discovery and development during her career. At Merck, she led an external research initiative, with responsibility for developing and implementing an integrated strategy for building Merck’s early pipeline using external sources of innovation.
At Schering-Plough, Dr. Strader had both strategic and operational responsibility for the company’s global small molecule and biologics discovery research portfolio, when she and her team initiated many of the programs that currently populate the Merck portfolio.
Dr. Strader received her B.S. in Chemistry from the University of Virginia and her Ph.D. in Chemistry from the California Institute of Technology. She did her postdoctoral training as a Howard Hughes Fellow in Robert Lefkowitz’s laboratory at Duke University and is the author of more than 150 scientific publications.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.
Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
For more information : http://www.acorda.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.